This volume is the second in the 'Cancer Treatment and Research' series focussing on basic and clinical tumor immunology. It has a rather different focus or emphasis from that of the first volume, published two years ago. That work (Basic and Clinical Tumor Immunology, R.B. Herberman, ed., Martinus Nijhoff Publishers, 1983) devoted considerable attention to up dated summaries in various areas of classical tumor immunology: specific antitumor immunity, the immunologic competence of cancer patietns, char acterization of human tumor-associated antigens, the ability to propagate specifically immune T cells in culture in the presence of interleukin 2, and the use of such cells for adoptive immunotherapy of established tumors. of evidence concerning the immune However, it also reviewed the status surveillance hypothesis and pointed out the need to consider non-T cell mediated mechanisms of host resistance. In particular, one chapter sum marized information on the role of macrophages in host resistance against tumors. The present volume continues to emphasize one of the major themes of the first volume, innovative approaches to the therapy of cancer. It involves contributions from leading investigators on several primary types of therapeutic interventions related to monoclonal antibodies, the col laboration of monoclonal antibodies with macro phages to mediate antibody dependent cellular cytotoxicity, lymphokines, tumor vaccines, and natural killer cells. It also has an up-to-date summary of the immunologic aspects of the exciting and promising work being performed on human T cell leukemia virus in the laboratory of Dr. Robert Gallo.

Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy examines the challenges of delivering immuno-oncology therapies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. Nanotechnology-based targeted delivery strategies could improve the delivery efficiency of IO agents as well as provide additional avenues for novel therapeutic and vaccination strategies. Additionally, a number of locally-administered immunogenic scaffolds and therapeutic strategies, such as the use of STING agonist, could benefit from rationally designed biomaterials and delivery approaches. Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side. Comprehensive treaty covering all aspects of immuno-oncology (IO) Novel strategies for delivery of IO therapeutics and vaccines Forecasting on the future of nanotechnology and drug delivery for IO

A FRESH EXAMINATION OF PRECISION MEDICINE'S INCREASINGLY PROMINENT ROLE IN THE FIELD OF ONCOLOGY Precision medicine takes into account each patient's specific characteristics and requirements to arrive at treatment plans that are optimized towards the best possible outcome. As the field of oncology continues to advance, this tailored approach is becoming more and more prevalent, channelling data on genomics, proteomics, metabolomics and other areas into new and innovative methods of practice. Precision Medicine in Oncology draws together the essential research driving the field forward, providing oncology clinicians and trainees alike with an illuminating overview of the technology and thinking behind the breakthroughs currently being made. Topics covered include: Biologically-guided radiation therapy Informatics for precision medicine Molecular imaging Biomarkers for treatment assessment Big data Nanoplatforms Casting a spotlight on this emerging knowledge base and its impact upon the management of tumors, Precision Medicine in Oncology opens up new possibilities and ways of working not only for oncologists, but also for molecular biologists, radiologists, medical geneticists, and others.

Part 1: Intratumoral Signatures Associated With Immune Responsiveness

Immunotherapy is a form of cancer therapy that harnesses the body's immune system to destroy cancer cells. In recent years, immunotherapies have been developed for several cancers, including advanced melanoma, lung cancer, and kidney cancer. In some patients with metastatic cancers who have not responded well to other treatments, immunotherapy treatment has resulted in complete and durable responses. Given these promising findings, it is hoped that continued immunotherapy research and development will produce better cancer treatments that improve patient outcomes. With this promise, however, there is also recognition that the clinical and biological landscape for immunotherapies is novel and not yet well understood. For example, adverse events with immunotherapy treatment are quite different from those experienced with other types of cancer therapy. Similarly, immunotherapy dosing, therapeutic responses, and response time lines are also markedly different from other cancer therapies. To examine these challenges and explore strategies to overcome them, the National Academies of Sciences, Engineering, and Medicine held a workshop in February and March of 2016. This report summarizes the presentations and discussions from the workshop.

Where do you begin to look for a recent, authoritative article on the diagnosis or management of particular malignancy? The few general oncology text books are generally out of date. Single papers in specialized journals are informative but seldom comprehensive; these are more often preliminary reports on a very limited number of patients. Certain general journals fre quently publish good in-depth reviews of cancer topics, and published sym posium lectures are often the best overviews available. Unfortunately, these reviews and supplements appear sporadically, and the reader can never be sure when a topic of special interest will be covered. Cancer Treatment and Research is a series of authoritative volumes which aim to meet this need. It is an attempt to establish a critical mass of oncology literature covering virtually all oncology topics, revised frequently to keep the coverage up to date, easily available on a single library shelf or by a single personal subscription. We have approached the problem in the following fashion. First, by divid ing the oncology literature into specific subdivisions such as lung cancer, genitourinary cancer, pediatric oncology, etc. Second, by asking eminent authorities in each of these areas to edit a volume on the specific topic on an annual or biannual basis. Each topic and tumor type is covered in a volume appearing frequently and predictably, discussing current diagnosis, staging, markers, all forms of treatment modalities, basic biology, and more.

Cancer Immunology is intended as an up-to-date, clinically relevant review of cancer immunology and immunotherapy. This volume focuses on the immunopathology and immunotherapy of organ cancers in detail. It clearly explains their immunology and describes novel immunotherapy for specific cancers, including pediatric solid tumors, hematologic malignancies, gastrointestinal tumors, skin cancers, bone and connective tissue tumors, central nervous system tumors, lung cancers, genitourinary tract tumors and breast cancers. In so doing, it builds on the previous two volumes in Cancer Immunology, placing basic knowledge on tumor immunology and immunotherapy into a clinical perspective with the aim of educating clinicians on advances in cancer immunology and the most recent approaches in the immunotherapy of various tumors. This translational, clinically oriented book will be of special value to clinical immunologists, hematologists and oncologists.